Laura Kummer

2024

Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

Keijzer, S., Oskam, N., Ooijevaar-de Heer, P., Steenhuis, M., Keijser, J. B. D., Wieske, L., van Dam, K. P. J., Stalman, E. W., Kummer, L. Y. L., Boekel, L., Kuijpers, T. W., ten Brinke, A., van Ham, S. M., Eftimov, F., Tas, S. W., Wolbink, G. J. & Rispens, T., 2024, In: Frontiers in immunology. 15, 1314507.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

van den Dijssel, J., Duurland, M. C., Konijn, V. A. L., Kummer, L. Y. L., Hagen, R. R., Kuijper, L. H., Wieske, L., van Dam, K. P. J., Stalman, E. W., Steenhuis, M., Geerdes, D. M., Mok, J. Y., Kragten, A. H. M., Menage, C., Koets, L., Veldhuisen, B., Verstegen, N. J. M., van der Schoot, C. E., van Esch, W. J. E., D'Haens, G. R. AM., & 10 othersLöwenberg, M., Volkers, A. G., Rispens, T., Kuijpers, T. W., Eftimov, F., van Gisbergen, K. P. JM., van Ham, S. M., ten Brinke, A., van de Sandt, C. E. & T2B! immunity against SARS-CoV-2 study group, 1 Apr 2024, In: Journal of autoimmunity. 144, 103175.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination

Valk, A. M., Keijser, J. B. D., van Dam, K. P. J., Stalman, E. W., Wieske, L., Steenhuis, M., Kummer, L. Y. L., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., Bosma, A. L., Horváth, B., Hijnen, D-J., Schreurs, C. R. G., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., & 10 othersWolbink, G. J., Keijzer, S., Derksen, N. I. L., van Deelen, M., van Mierlo, G., Kuijpers, T. W., Eftimov, F., van Ham, S. M., ten Brinke, A. & Rispens, T., 2024, (E-pub ahead of print) In: Allergy: European Journal of Allergy and Clinical Immunology.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

2023

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

Rispens, T., Marieke van Ham, S. & the T2B! immunity against SARS-CoV-2 study group, 1 Feb 2023, In: Journal of autoimmunity. 135, 102984.

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

van Kempen, Z. L. E., van Dam, K. P. J., Keijser, J. B. D., Stalman, E. W., Kummer, L. Y. L., Strijbis, E. M. M., Steenhuis, M., ten Brinke, A., van Ham, S. M., Kuijpers, T., Rispens, T., Eftimov, F., Wieske, L. & Killestein, J., 9 Nov 2023, (E-pub ahead of print) In: MULTIPLE SCLEROSIS JOURNAL. p. 13524585231207761

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis

the T2B! immunity against SARS-CoV-2 study group & T2B! immunity against SARS-CoV-2 study group, Jan 2023, In: Annals of neurology. 93, 1, p. 103-108 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

2 Citations (Scopus)

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Wieske, L., Stalman, E. W., van Dam, P. J. K., Kummer, L. Y., Steenhuis, M., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G., van der Kooi, A., Raaphorst, J., Löwenberg, M., Takkenberg, B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., & 38 othersBosma, A. L., Hilhorst, M. L., Vegting, Y., Bemelman, F. J., Voskuyl, A., Broens, B., Parra Sanchez, A., van Els, C. C. A. C. M., Wit, J. D., Rutgers, A., de Leeuw, K., Horváth, B., Verschuuren, J. J. G. M., Ruiter, A. M., van Ouwerkerk, L., van der Woude, D., Allaart, C. F., Teng, Y. K. O., van Paassen, P., Busch, M. H., Jallah, P. B. P., Brusse, E., van Doorn, P. A., Baars, A. E., Hijnen, D., Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Keijzer, S., Keijser, J., Cristianawati, O., ten Brinke, A., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., Kuijpers, T. W., Rispens, T. & Eftimov, F., 1 Jun 2023, In: Annals of the rheumatic diseases. 82, 6, p. 883-885 3 p., ard-2022-223464.

Research output: Contribution to journal › Review article › Academic › peer-review

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

ten Brinke, A., Rispens, T. & on behalf of the T2B! immunity against SARS-CoV-2 study group, 1 Dec 2023, In: BMC Infectious Diseases. 23, 1, 332.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

1 Citation (Scopus)

SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis

van Kempen, Z. L. E., Stalman, E. W., Steenhuis, M., Kummer, L. Y. L., van Dam, K. P. J., Wilbrink, M. F., ten Brinke, A., van Ham, S. M., Kuijpers, T., Rispens, T., Eftimov, F., Wieske, L., Killestein, J., T2B! immunity against SARS-CoV-2 study group, Hilhorst, M. L. & Bemelman, F. J., 1 Apr 2023, In: Journal of neurology, neurosurgery, and psychiatry. 94, 4, p. 280-283 4 p., jnnp-2022-330100.

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

2022

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

Boekel, L., Hooijberg, F., Vogelzang, E. H., Besten, Y. R., Leeuw, M., Atiqi, S., van Vollenhoven, R. F., Wijbrandts, C. A., Gerritsen, M., Krieckaert, C., Dijkshoorn, B., Bakhlakh, S., Crooijmans, J. J., Voskuyl, A., van der Horst-Bruinsma, I. E., Lems, W., Kuijpers, T. W., van Ham, S. M., Wieske, L., Eftimov, F., & 13 othersKummer, L. Y., van Dam, P. K., Stalman, E. W., Steenhuis, M., Keijzer, S., Cristianawati, O., Keijser, J., Loeff, F. C., Tas, S. W., Nurmohamed, M. T., Boers, M., Rispens, T. & Wolbink, G., 5 Apr 2022, In: RMD OPEN. 8, 1, 002035.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

12 Citations (Scopus)

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

Wieske, L., van Dam, K. P. J., Kummer, L. Y., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Boekel, L., Wolbink, G. J., van der Kooi, A. J., Raaphorst, J., Löwenberg, M., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., Bosma, A. L., Hilhorst, M. L., Vegting, Y., Voskuyl, A. E., & 33 othersBroens, B., Parra Sanchez, A., van Els, C. C. A. C. M., Rutgers, A., de Leeuw, K., Horváth, B., Verschuuren, J. J. G. M., Ruiter, A. M., van Ouwerkerk, L., van der Woude, D., Allaart, C. F., Teng, O. Y. K., van Paassen, P., Busch, M. H., Jallah, P. B. P., Brusse, E., van Doorn, P. A., Baars, A. E., Hijnen, D. J., Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Steenhuis, M., Keijzer, S., Keijser, J. B. D., Boogaard, A., Cristianawati, O., ten Brinke, A., Zwinderman, K. A. H., Rispens, T., Kuijpers, T. W., Eftimov, F. & T2B! immunity against SARS-CoV-2 study group, 5 Sept 2022, In: Annals of the rheumatic diseases. 81, 12, p. 1757-1766 10 p., 222904.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

11 Citations (Scopus)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

T2B! immunity against SARS-CoV-2 study group, 1 Jun 2022, In: The Lancet Rheumatology. 4, 6, p. e417-e429

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

34 Citations (Scopus)

Erratum: Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod (Neurol Neuroimmunol Neuroinflamm (2022) 9: 4 (e1178) DOI: 10.1212/NXI.0000000000001178)

Palomares Cabeza, V., Kummer, L. Y. L. & Wieske, L., 26 Nov 2022, In: Neurology® neuroimmunology & neuroinflammation. 9, 6, e200036.

Research output: Contribution to journal › Erratum/Corrigendum › Academic

Open Access

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

T2B! immunity against SARS-CoV-2 study group, ten Brinke, A., Zwinderman, K. A. H., Rispens, T., van Gils, M. J. & Verstegen, N. J. M., 1 May 2022, In: The Lancet Rheumatology. 4, 5, p. e338-e350

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

81 Citations (Scopus)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273

T2B! immunity against SARS-CoV-2 study group & On behalf of the T2B immunity against SARS-CoV-2 study group, 15 Jul 2022, In: eLife. 11, 26 p., e77969.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

10 Citations (Scopus)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination

the T2B! immunity against SARS-CoV-2 study group & T2B! immunity against SARS-CoV-2 study group, 10 Nov 2022, In: Frontiers in Neurology. 13, 6 p., 1032830.

Research output: Contribution to journal › Article › Academic › peer-review

Open Access

1 Citation (Scopus)